Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526485 · ClinicalTrials.gov registry record
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 15
- Enrollment target
NCT02526485: Completed study, sponsored by Vanderbilt University Medical Center.
NCT02526485 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02526485 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Primary Outcome
Functional assay confirming presence of heparin-induced thrombocytopenia
Interventions
- PROCEDURE Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-09-05 |
What the finished NCT02526485 record still lists
NCT02526485 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Draw is the first listed.
NCT02526485 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02526485 about?
NCT02526485 is a clinical study titled "Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2". The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prev...
What is the current status of trial NCT02526485?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2015-03. Estimated completion is 2018-09-05.
What interventions are being tested in trial NCT02526485?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02526485?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia